Starting from 2021, Sumitomo Pharma (Suzhou) Co., Ltd.has participated in the academic exchange seminars on blood pressure management hosted by the China Hypertension League and the Shanghai Institute of Hypertension. Attracting 30,000 attendees, the project invites renowned experts in the cardiovascular field monthly to share their views on topics including intelligent hypertension management and reduction of the burden of cardiovascular diseases, which promotes China's hypertension control action plan and contributes to the awareness of increasing rates of hypertension and treatment strategies.

In 2021, Sumitomo Pharma (Suzhou) Co., Ltd. and Zhongguancun Nephrology & Blood Purification Innovation Alliance invited more than 100 experts in the field of kidney disease and blood purification and 15,000 industry professionals to participate in the conference. They conducted comprehensive knowledge exchanges on the management and treatment of hypertensive complications in patients with chronic kidney disease and explored new applications of antihypertensive drugs under new target values for blood pressure, aiming to improve the level of blood purification treatment in China and bring new hope to patients with chronic kidney disease.

The company participated in the 2020 Hypertension Standardization Online Education Project organized by the institute to strengthen and normalize the standardized diagnosis and management of hypertension in China, learn from the development trend of the latest international studies, discuss the new situation and strategies in the related fields, continuously improve the quality of clinical care, and comprehensively promote the development of diagnosis and treatment in the field of chronic diseases in China.

The Li Ma Grassroots and Healthy Blood Pressure of the Grassroots Project has been carried out since 2018. The project has been upgraded in 2019. Through strong cooperation with various institutes and multi-channel online and offline projects, the company has been committed to improving the concept of diagnosis and treatment of primary care physicians and increasing the awareness and accessibility of hypertension prevention and treatment in primary care.

By monitoring blood pressure in different places and under different conditions with five large and medium-sized enterprises in Shanghai, the company helps primary care physicians and voluntary workers to explore the appropriate hypertension management for young and middle-aged workers, providing evidence and experiences for the future optimization of hypertension management strategies and methods for young and middle-aged people.

In cooperation with institutes, the company is committed to training school doctors and improving hypertension prevention and treatment by organizing training activities for school doctors in major universities in Beijing, aiming to improve the awareness level of hypertension among university staff and students, popularize prevention and treatment knowledge, promote hypertension prevention and treatment, actively respond to Health China 2030, and contribute to the enhancement of people's health.

Through the online meeting mode with the cooperation of authoritative medical media platforms, the company creates a multi-dimensional online academic platform to collaborate with experts, spread the academic voice, and provide a professional communication platform for clinicians.

Based on the construction in the field of hypertension diagnosis and treatment, Sumitomo Pharma (Suzhou) Co., Ltd. has built a series of academic platforms named Winged Steed for young physicians to develop their clinical practice skills. Over the past 10 years, the activities have taken the form of case sharing, debates, talk shows, and speech kings, and have been continuously innovated, providing an academic stage for more than a thousand doctors to share their valuable practical experience. From evidence-based to practice, it has been continuously promoting the standardized clinical management of blood pressure.